Regulus Announces Pricing of Public Offering of Common Stock

         Regulus Announces Pricing of Public Offering of Common Stock

PR Newswire

LA JOLLA, Calif., July 17, 2013

LA JOLLA, Calif., July 17, 2013 /PRNewswire/ --Regulus Therapeutics Inc.
(NASDAQ: RGLS), a biopharmaceutical company leading the discovery and
development of innovative medicines targeting microRNAs, announced today the
pricing of a public offering of 4,500,000 shares of its common stock at a
price of $9.50 per share. The gross proceeds to Regulus from this offering
are expected to be approximately $42.8 million, before deducting underwriting
discounts and commissions and estimated offering expenses payable by
Regulus.The offering is expected to close on or about July 22, 2013, subject
to customary closing conditions. Regulus has also granted the underwriters a
30-day option to purchase up to an additional 675,000 shares at the public
offering price to cover overallotments, if any.

Lazard Capital Markets LLC, Cowen and Company, LLC and BMO Capital Markets
Corp are acting as joint book-running managers for the offering. Needham &
Company, LLC and Wedbush PacGrow Life Sciences are acting as co-managers.

A registration statement relating to these securities was declared effective
by the Securities and Exchange Commission on July 16, 2013.

The offering is being made only by means of a prospectus, copies of which may
be obtained from Lazard Capital Markets LLC, Attn: Syndicate Department, 30
Rockefeller Plaza, 48th Floor, New York, NY 10112, Telephone: (800) 542-0970;
from Cowen and Company, LLC (c/o Broadridge Financial Services, 1155 Long
Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, Telephone:
(631) 274-2806, Fax: 631-254-7140); or from BMO Capital Markets Corp,
Attention: Equity Syndicate Department, 3 Times Square New York, NY 10036,
Telephone: (800) 414-3627, E-mail:

This press release shall not constitute an offer to sell or the solicitation
of an offer to buy these securities, nor shall there be any sale of these
securities in any state or other jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such state or other

About Regulus

Regulus Therapeutics Inc. is a biopharmaceutical company leading the discovery
and development of innovative medicines targeting microRNAs. Regulus is
leveraging a mature therapeutic platform based on technology that has been
developed over 20 years. Regulus works with a broad network of academic
collaborators and leverages the oligonucleotide drug discovery and development
expertise of its founding companies, Alnylam Pharmaceuticals and Isis
Pharmaceuticals. Regulus is developing RG-101 for the treatment of HCV and is
advancing other microRNA therapeutics toward clinical development in several
areas, including oncology, fibrosis and metabolic diseases. Regulus has formed
strategic alliances with AstraZeneca, GlaxoSmithKline and Sanofi and a
research collaboration with Biogen Idec.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not
historical facts are "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995, including statements with
respect to the completion, timing and size of the offering and the expected
gross proceeds from the offering, Regulus' expectations regarding future
therapeutic and commercial potential of Regulus' business plans, and
technologies and intellectual property related to microRNA therapeutics being
discovered and developed by Regulus. Because such statements are subject to
risks and uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Words such as
"believes," "anticipates," "plans," "expects," "intends," "will," "goal,"
"potential" and similar expressions are intended to identify forward-looking
statements. These forward-looking statements are based upon Regulus' current
expectations and involve assumptions that may never materialize or may prove
to be incorrect. Actual results and the timing of events could differ
materially from those anticipated in such forward-looking statements as a
result of various risks and uncertainties, which include, without limitation,
risks associated with market conditions and the satisfaction of closing
conditions related to the proposed public offering, the process of
discovering, developing and commercializing drugs that are safe and effective
for use as human therapeutics, and in the endeavor of building a business
around such drugs. These and other risks concerning Regulus' programs are
described in additional detail in Regulus' filings with the Securities and
Exchange Commission, including its quarterly report on Form 10-Q for the
quarter ended March 31, 2013. All forward-looking statements contained in
this press release speak only as of the date on which they were made. Regulus
undertakes no obligation to update such statements to reflect events that
occur or circumstances that exist after the date on which they were made.

SOURCE Regulus Therapeutics Inc.

Contact: Amy Conrad, Director, Investor Relations and Corporate
Communications, Regulus Therapeutics Inc., +1-858-202-6300,, David Schull, Russo Partners LLC, +1-212-845-4271,
Press spacebar to pause and continue. Press esc to stop.